Association For Accessible Medicines
DC · 17 filings, 2025
What the money shows
Association FOR Accessible Medicines reported $3.1M in federal lobbying for 2025 across 17 filings. The filings name 5 lobbying firms, led by Squire Patton BOGGS and FOLEY & Lardner. The filing text lists 8 issue areas.
Sources: Senate LDA · FEC
The Association for Accessible Medicines (AAM), Washington, D.C., is a trade association representing the manufacturers and distributors of generic prescription drugs, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the U.S. generic drug industry. As the primary lobby for makers of generic drugs, AAM's stated mission is to advocate for public policies that facilitate timely access to lower-cost, FDA-approved generic and biosimilar medicines by consumers and patients. Over the 10-year period 2008 through 2018, the use of generic drugs generated $2 trillion in U.S. healthcare savings. via Wikipedia ↗
1Lobbies on
Its filings list: Trade (domestic/foreign) · Pharmacy · Copyright/Patent/Trademark · Health Issues · Manufacturing · Labor Issues/Antitrust/Workplace · Medicare/Medicaid · Budget/Appropriations
2Through these firms · 5
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5224A bill to improve training for airport drivers in the movement area at commercial service airports through…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…
- S 5226A bill to require social media platform providers to obtain parental consent with respect to children creat…